Medinet Co Ltd
Medinet Co Ltd provides healthcare diagnostics services, primarily generating revenue through the development and sale of diagnostic products and related services.
Business. Medinet Co Ltd (2370.T) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Japan and is primarily listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Medinet Co Ltd (2370.T) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Japan and is primarily listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Medinet Co Ltd maintains a strong liquidity position, with cash and equivalents amounting to ¥4.9 billion, representing 80% of total assets. The company's liquidity FPT score indicates a low liquidity risk, supported by a current ratio of 20.28, which is significantly higher than the industry median. However, the company reported negative operating cash flow of ¥573.4 million, indicating a reliance on non-operational sources for liquidity.
Profitability metrics show a challenging performance, with a net loss of ¥341.6 million and an operating loss of ¥364.8 million. The return on equity (ROE) is -6.14%, and the return on assets (ROA) is -5.6%, both well below the industry median for profitability. The gross profit of ¥204.5 million represents a small margin of 1.35% of revenue, highlighting the company's cost structure challenges.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare diagnostics sector. The absence of long-term debt and a debt-to-equity ratio of 0.0 suggests a conservative capital structure, but also limits financial leverage.
Growth trajectory is constrained by the current financial performance, with no disclosed revenue growth in the most recent period. The company's market cap of ¥7.8 billion is significantly lower than its total equity value, indicating a potential undervaluation. However, the negative operating income and net loss suggest that the company is not currently generating sustainable earnings.
Risk factors include the company's negative operating cash flow and net loss, which could impact its ability to fund operations and invest in growth. The risk assessment indicates low dilution potential, with no immediate filing-based liquidity or dilution flags detected. The valuation adjustments applied in the custom valuations do not indicate significant overvaluation or undervaluation.
Recent events include the latest financial filing, which disclosed the company's negative operating and net income. No recent earnings call transcripts or significant regulatory filings were identified that would indicate material changes in the company's strategic direction or risk profile.
- Medinet Co Ltd has a strong liquidity position with ¥4.9 billion in cash and equivalents, but reports negative operating cash flow.
- The company's profitability is weak, with a net loss of ¥341.6 million and an ROE of -6.14%.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's market cap is lower than its total equity value, suggesting potential undervaluation.
- No immediate liquidity or dilution risks were identified in the risk assessment.
- "margin_outlook_rationale": "The company's gross margin is low at 1.35%, and the negative operating income suggests margin compression is likely to continue.",
Bull / Bear case
Generated · model-assistedMedinet's cash conversion ratio of 1.68 ranks as best-in-class among 565 biotechnology peers.
Operating margin of -2.41% exceeds the biotechnology cohort median of -2.56%, indicating relative efficiency.
Revenue grew at a 6.3% compound annual growth rate over the last four fiscal years.
The company carries zero long-term debt, resulting in a debt-to-equity ratio of 0.0.
Medinet faces high credit risk according to the provided risk flag assessment for the issuer.
The company reported a net loss of 1.36 billion JPY in the most recent fiscal year.
Free cash flow deteriorated by 5.8% year-over-year to a negative 1.29 billion JPY.
Operating income declined by 5.4% year-over-year to a loss of 1.47 billion JPY.
In focus — financials by report
Revenue ¥633.7M, −7,2% YoY; Operating income −20,0% YoY.
- ▍Revenue ¥633.7M, −7,2% YoY
- ▍Operating income −20,0% YoY
- ▍Net income −48,7% YoY
- ▍Free cash flow −55,9% YoY
- ▍Net margin -197.9%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Medinet Co Ltd Market data — financials · 2026-05-26